Found 26 Multiple Myeloma trials
A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 26417: A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability Efficacy Pharmacokinetics and Immunogenicity of TAK-573 (formerly TEV-48573) Administered Intravenously as a Single Agent in Patients with Refractory Multiple Myeloma
Request for collaborative review: WIRB serving as IRB of record.
PHASE I TRIAL OF AUTOLOGOUS T CELLS ENGINEERED TO EXPRESS NY-ESO-1 TCR AND GENE EDITED TO ELIMINATE ENDOGENOUS TCR AND PD-1
This is a Phase 1 first-in-human trial proposed to determine the safety profile and manufacturing feasibility of a single infusion of NYCE T cells on adult patients with myeloma, synovial sarcoma, and myxoid/round cell liposarcoma, and melanoma who have relapsed or refractory tumors expressing NY-ESO-1 antigen.
UPCC 17419: A Phase 1b-2 Open-Label Study of JNJ-68284528 a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to investigate the use of a new, experimental drug called JNJ-68284528 in subjects with multiple myeloma.
A Phase 1 Open-Label Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). …
UPCC 22420: A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma
The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab) and to characterize the safety of each RP2D for selected treatment combinations. Patients from within the Penn Medicine Cancer Center will be approached as potential participants.
Measurement of B cell maturation antigen-Directed CAR T Cells During TAK-573 Study Participation
The primary objective of this pilot study is to explore in a preliminary fashion whether administration of TAK-573 increases the number of BCMA-specific T cells in blood samples from patients with myeloma.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)
The purpose of this study is to see if JNJ-68284528 is safe and useful for treating patients with relapsed or refractory multiple myeloma.
UPCC 37420 Phase 2 Study of Belantamab Mafodotin As Pre- and Post- Autologous Stem Cell Transplant Consolidation and Maintenance For Multiple Myeloma
The research study is being conducted to see if combining an investigational drug, called belantamab mafodotin, with standard-of-care autologous stem cell transplant and maintenance therapy in patients with myeloma can help reduce the amount of myeloma cells that can be detected in patients after transplant. We will also study if …
UPCC 39422 Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma
he purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.
Phase I Study of Tasquinimod Alone and in Combination with Standard Therapy for Relapsed or Refractory Myeloma
The research study is being conducted to understand the effects of tasquinimod, an experimental medication, on patients with myeloma. Eligibile subject have multiple myeloma that has been previously treated and is now in need of additional treatment. Part 1 of this study evaluates tasquinimod alone. Part 2 of this study …
Please choose between Voice or SMS based delivery of verification code
or